Physician profile
Mark H Kramar
NPI 1174568414
$3,513.57
in general payments reported to CMS, 2019-2025
23 companies · $655 in 2025
The $655 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $189 · 2021: $161 · 2022: $837 · 2023: $391 · 2024: $749 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,794.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $791.41 | 2019-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $405.47 | 2019-2025 | Xelpros, Cequa |
| Alcon Vision LLC | $368.97 | 2021-2025 | Clareon Panoptix Pro, Ngenuity, Tryptyr |
| Optos, INC. | $225.61 | 2022 | |
| Aerie Pharmaceuticals, INC. | $217.33 | 2019-2021 | |
| Sight Sciences, INC. | $189.03 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Harrow Eye, LLC | $167.67 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $143.14 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.91 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $119.58 | 2022-2023 | |
| Abbvie INC. | $112.78 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $109.72 | 2022-2025 | Miebo, Scoutpro Osmolarity System |
| Dompe US, INC. | $97.06 | 2022-2024 | Oxervate |
| Allergan, INC. | $85.29 | 2021-2022 | |
| Thea Pharma INC. | $70.81 | 2023-2025 | Iyuzeh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $64.90 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $50.19 | 2022 | |
| Eyevance Pharmaceuticals LLC | $47.70 | 2022 | |
| Rxsight INC | $31.15 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $24.95 | 2023 | Tyrvaya |
| Akorn, INC. | $22.95 | 2019 | |
| Biotissue Holdings INC. | $16.25 | 2022 | |
| Akorn Operating Company LLC | $14.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kramar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.